This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): intetumumab
Description: CNTO 95 is a monoclonal antibody that binds to avß3 and avß5 integrins. Available evidence shows that avß3 and avß5 promote angiogenesis through different pathways.
CNTO 95 was generated by Centocor using Medarex's UltiMAb technology.
Deal Structure: In May 1997, Medarex announced that it signed adefinitive agreement to acquire GenPharm International for up to$65 million in Medarex common stock. Through this acquisition, Medarex willexpand its business and technology base to include GenPharm's patentedHuMab-Mouse, an antibody discovery platform that complements Medarex'spatented Bispecific antibody technology.
In May 2000, Medarex announced that Centocor has exercised its option to obtainexclusive commercial licenses to fully human antibodies to four antigenscreated with Medarex's HuMAb-Mouse technology.
In September 2007, Medarex announced the extension of a broad antibody development relationship with itslicensing partner, Centocor R&D. The extended relationship providesCentocor with continued access to Medarex's UltiMAb Human Antibody DevelopmentSystem (which includes HuMAb-Mouse technology) for the generation of fully human antibodies to an unlimited number oftargets.
Under the terms of the new agreement,...See full deal structure in Biomedtracker
Partners: Bristol-Myers Squibb Company
CNTO 95 News
Additional information available to subscribers only: